Ítem
Acceso Abierto

The role of the AR/ER ratio in ER-positive breast cancer patients

Mostrar el registro sencillo de la publicación
dc.creatorRangel, Nelsonspa
dc.creatorRondon-Lagos, Milenaspa
dc.creatorAnnaratone, Lauraspa
dc.creatorOsella-Abate, Simonaspa
dc.creatorMetovic, Jasnaspa
dc.creatorMano, Maria Pieraspa
dc.creatorBertero, Lucaspa
dc.creatorCassoni, Paolaspa
dc.creatorSapino, Annaspa
dc.creatorCastellano, Isabellaspa
dc.date.accessioned2020-05-26T00:06:43Z
dc.date.available2020-05-26T00:06:43Z
dc.date.created2018spa
dc.description.abstractThe significance of androgen receptor (AR) in breast cancer (BC) management is not fully defined, and it is still ambiguous how the level of AR expression influences oestrogen receptor-positive (ER+) tumours. The aim of the present study was to analyse the prognostic impact of AR/ER ratio, evaluated by immunohistochemistry (IHC), correlating this value with clinical, pathological and molecular characteristics. We retrospectively selected a cohort of 402 ER+BC patients. On each tumour, IHC analyses for AR, ER, PgR, HER2 and Ki67 were performed and AR+ cases were used to calculate the AR/ER value. A cut-off of >2 was selected using receiver-operating characteristic (ROC) curve analyses. RNA from 19 cases with AR/ER>2 was extracted and used for Prosigna-PAM50 assays. Tumours with AR/ER>2 (6%) showed more frequent metastatic lymph nodes, larger size, higher histological grade and lower PgR levels than cases with AR/ER less than 2. Multivariate analysis confirmed that patients with AR/ER>2 had worse disease-free interval (DFI) and disease-specific survival (DSS) (hazard ratios (HR) = 4.96 for DFI and HR = 8.69 for DSS, both P less than 0.004). According to the Prosigna-PAM50 assay, 63% (12/19) of these cases resulted in intermediate or high risk of recurrence categories. Additionally, although all samples were positive for ER assessed by IHC, the molecular test assigned 47.4% (9/19) of BCs to intrinsic non-luminal subtypes. In conclusion, the AR/ER ratio >2 identifies a subgroup of patients with aggressive biological features and may represent an additional independent marker of worse BC prognosis. Moreover, the Prosigna-PAM50 results indicate that a significant number of cases with AR/ER>2 could be non-luminal tumours. © 2018 Society for Endocrinology Printed in Great Britain Published by Bioscientifica Ltd.eng
dc.format.mimetypeapplication/pdf
dc.identifier.doihttps://doi.org/10.1530/ERC-17-0417
dc.identifier.issn13510088
dc.identifier.urihttps://repository.urosario.edu.co/handle/10336/23923
dc.language.isoengspa
dc.publisherBioScientifica Ltd.spa
dc.relation.citationEndPage172
dc.relation.citationIssueNo. 3
dc.relation.citationStartPage163
dc.relation.citationTitleEndocrine-Related Cancer
dc.relation.citationVolumeVol. 25
dc.relation.ispartofEndocrine-Related Cancer, ISSN:13510088, Vol.25, No.3 (2018); pp. 163-172spa
dc.relation.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85042622495&doi=10.1530%2fERC-17-0417&partnerID=40&md5=226019272900e7b4de15c6bd1e65f996spa
dc.rights.accesRightsinfo:eu-repo/semantics/openAccess
dc.rights.accesoAbierto (Texto Completo)spa
dc.source.instnameinstname:Universidad del Rosariospa
dc.source.reponamereponame:Repositorio Institucional EdocURspa
dc.subject.keywordAndrogen receptorspa
dc.subject.keywordandrogeneng
dc.subject.keywordEstrogen receptorspa
dc.subject.keywordKi 67 antigenspa
dc.subject.keywordProgesterone receptorspa
dc.subject.keywordTumor markerspa
dc.subject.keywordAndrogen receptorspa
dc.subject.keywordAr proteineng
dc.subject.keywordEstrogen receptorspa
dc.subject.keywordAdultspa
dc.subject.keywordAgedspa
dc.subject.keywordArticlespa
dc.subject.keywordCancer gradingspa
dc.subject.keywordCancer patientspa
dc.subject.keywordCancer prognosisspa
dc.subject.keywordCancer recurrencespa
dc.subject.keywordCancer survivalspa
dc.subject.keywordCohort analysisspa
dc.subject.keywordControlled studyspa
dc.subject.keywordDisease free intervalspa
dc.subject.keywordDisease specific survivalspa
dc.subject.keywordEstrogen receptor positive breast cancerspa
dc.subject.keywordFemalespa
dc.subject.keywordHistopathologyspa
dc.subject.keywordHumanspa
dc.subject.keywordHuman tissuespa
dc.subject.keywordImmunohistochemistryspa
dc.subject.keywordLuminal a breast cancerspa
dc.subject.keywordLuminal b breast cancerspa
dc.subject.keywordLymph node metastasisspa
dc.subject.keywordMajor clinical studyspa
dc.subject.keywordMastectomyspa
dc.subject.keywordPartial mastectomyspa
dc.subject.keywordRecurrence riskspa
dc.subject.keywordRetrospective studyspa
dc.subject.keywordSurvival ratespa
dc.subject.keywordTumor volumespa
dc.subject.keywordBreast tumorspa
dc.subject.keywordMetabolismspa
dc.subject.keywordMiddle agedspa
dc.subject.keywordPathologyspa
dc.subject.keywordPrognosisspa
dc.subject.keywordVery elderlyspa
dc.subject.keywordAdultspa
dc.subject.keywordAgedspa
dc.subject.keywordAged, 80 and overspa
dc.subject.keywordBreast neoplasmsspa
dc.subject.keywordFemalespa
dc.subject.keywordHumansspa
dc.subject.keywordMiddle agedspa
dc.subject.keywordPrognosisspa
dc.subject.keywordReceptorseng
dc.subject.keywordReceptorseng
dc.subject.keywordAndrogen receptorspa
dc.subject.keywordBreast cancerspa
dc.subject.keywordOestrogen receptorspa
dc.subject.keywordProsignaspa
dc.subject.keywordSubtypesspa
dc.titleThe role of the AR/ER ratio in ER-positive breast cancer patientsspa
dc.typearticleeng
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersion
dc.type.spaArtículospa
Archivos
Bloque original
Mostrando1 - 1 de 1
Miniatura
Nombre:
14796821-Endocrine-Related-Cancer-The-roleof-the-AR_ER-ratio-in-ER-positive-breast-cancer-patients.pdf
Tamaño:
1.52 MB
Formato:
Adobe Portable Document Format
Descripción:
Descargar
Colecciones
Artículos